Alexandria Hammond
Stock Analyst at B of A Securities
(1.78)
# 3,142
Out of 4,876 analysts
16
Total ratings
54.55%
Success rate
-2.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $56.28 | +13.72% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $521.00 | +120.73% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $24.24 | +3.14% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $27.54 | +45.24% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $78.83 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $795.12 | +25.77% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $152.01 | +24.99% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $107.62 | +2.21% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $46.65 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $126.92 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $186.79 | +9.75% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $299.51 | -49.92% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $9.95 | +201.51% | 1 | Apr 22, 2024 |
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $56.28
Upside: +13.72%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $521.00
Upside: +120.73%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $24.24
Upside: +3.14%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $27.54
Upside: +45.24%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $78.83
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $795.12
Upside: +25.77%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $152.01
Upside: +24.99%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $107.62
Upside: +2.21%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $46.65
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $126.92
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $186.79
Upside: +9.75%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $299.51
Upside: -49.92%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $9.95
Upside: +201.51%